Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia
| Autor: | Geraldine S. Hall, Robin K. Avery, Jennifer K. Long, Toni K. Choueiri, Mikkael A. Sekeres |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
biology
medicine.drug_class business.industry Antibiotics Myeloid leukemia General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease biology.organism_classification Enterococcus faecalis Microbiology carbohydrates (lipids) chemistry.chemical_compound chemistry Linezolid polycyclic compounds medicine lipids (amino acids peptides and proteins) Daptomycin business Febrile neutropenia medicine.drug Enterococcus faecium Antibacterial agent |
| Zdroj: | Mayo Clinic Proceedings. 80:1215-1216 |
| ISSN: | 0025-6196 |
| DOI: | 10.4065/80.9.1215 |
| Popis: | Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis , making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|